CAJ | 학술논문

化学治疗晚期非小细胞肺癌(NSCLC)疗效已达到平台,靶向药物是进一步提高疗效的关键.表皮生长因子受体(EGFR)信号异常在NSCLC的发生和进展中起重要作用,已成为抗肿瘤治疗的常用靶点.研究显示,小分子口服EGFR酪氨酸激酶抑制剂吉非替尼和厄洛替尼毒副作用轻微,对化疗失败的NSCLC患者可以改善症状、提高生活质量、延长生存.此外,抗EGFR单克隆抗体西妥昔单抗(cetuximab)在晚期NSCLC的一线和二线治疗中均显示出令人鼓舞的疗效.第二代靶向治疗药物--多靶点抑制剂,可同时阻断肿瘤多个信号传导,临床试验初步结果表明,毒副作用可以耐受,治疗晚期NSCLC有较好的应用前景.
화학치료만기비소세포폐암(NSCLC)료효이체도평태,파향약물시진일보제고료효적관건.표피생장인자수체(EGFR)신호이상재NSCLC적발생화진전중기중요작용,이성위항종류치료적상용파점.연구현시,소분자구복EGFR락안산격매억제제길비체니화액락체니독부작용경미,대화료실패적NSCLC환자가이개선증상、제고생활질량、연장생존.차외,항EGFR단극륭항체서타석단항(cetuximab)재만기NSCLC적일선화이선치료중균현시출령인고무적료효.제이대파향치료약물--다파점억제제,가동시조단종류다개신호전도,림상시험초보결과표명,독부작용가이내수,치료만기NSCLC유교호적응용전경.
The results of chemotherapy in the treatment of advanced non-small-cell lung cancer (NSCLC)had reached a plateau.Targeted therapy is the key to improving efficacy.In the last 5 years the epidermal growth factor receptor(EGFR)has emerged as one of the most important targets for drug development in oncology.Small molecules that inhibit the tyrosine kinase(TK)domain of EGFR have become new critical weapons in the treatment of NSCLC.Monoclonal antibodies targeting the external domain of EGFR have been shown to have clinical benefit when combined with chemotherapy.Recent data suggest that multitargeted inhibitors might have greater activity owing to their ability to simultaneously block key signaling pathways.Preliminary results of such agents in clinical trials shows that they have a well-tolerated toxicity profile,and might have a promising value in the treatment of advanced non-small-cell lung cancer.